

Pascale Guitera MD, PhD, FACD

Doctor es sciences, Dermatologist, Associate Professor

Sydney Medical School

Central Clinical School

Discipline of Dermatology

The University of Sydney

INDEX

	Page
1. Summary	3
2. Teaching Portfolio	4
Teaching Experience	4
Self-Evaluation of teaching & student learning	6
Evidence of Research in teaching	8
3. Research & Scholarship	8
Summary & Impact	8
Publications	9
Conference & Presentations	13
Workshop	17
Funded research awards	17
Collaboration of high stature	18
Research awards	19
Contribution to research organizations	20
Dissemination/ popularisation of research	23
4. Service & Leadership in the University & Discipline	24
Appointments	24
Professional activity	24

1- Summary

Employment Address:

- 1- Sydney Melanoma Diagnostic Centre, Sydney Cancer Centre, Royal Prince Alfred Hospital, Missenden Rd., Camperdown, NSW, 2050.
- 2- Melanoma Institute Australia, 40 Rocklands Road, North Sydney, NSW, 2060.
- 3- Discipline of Dermatology, Sydney University, NSW, 2050.

Email: Pascale@guitera.com

SMDC : Phone: (02) 9515 8537 Fax: (02) 9515 5278

MIA : Phone (02) 9911 7277 Fax (02) 9922 7220

Mob: 0434289455

Residential Address: 350 Arden St, 2034 Coogee, NSW

Present Position: 50% clinical/ 50% research

- Senior Researcher level D step 1, Sydney Medical School, Discipline of Dermatology (Central Clinical School), The University of Sydney.
- Director, Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital
- Director of the Dermatology Department, Melanoma Institute Australia

Qualifications: MD. PhD. FACD

Place of Birth: France; Australian citizenship: 2009; Married, 3 kids.

Curriculum Vitae Summary

- 1995 **MB –BS** -French equivalent of Medical Finals (selection exam to qualify as medical specialist). (ranked 29th in Paris from >2000 candidates).
- 1998-2000 **Master of Science** in Immunopathology (Paris V University and at the Genocentre, Evry). ‘Chimerical receptor anti-lymphocytes T and anti-lymphocytes B’.
- April 2002 **Medical Doctorate (MD)(1st class: médaille d’argent)** (Paris VII University) at Lariboisière Hospital, **Specialized in Dermatology and Venereology** in France.
- 2002-2004 **Fellowship** Dermatology Department at St Louis Hospital, Paris, (32 dermatology inpatients)
- 2006 -2009 **PhD at the Doctoral School of Cancer 0418, Paris XI University**, with Francois Amblard as Director from the Curie Institute and Pr Scott Menzies, from the University of Sydney as adjunct co-directors: ‘New imaging methods for the diagnosis of primary cutaneous melanoma and its metastasis.’
Passing with the highest award: congratulations of the jury

2008	Fellowship of the Australasian College of Dermatology (granted directly on curriculum)
2013- current	Registration as a Research Supervisor of Higher Degree Research Candidates, University of Sydney.
2013- current	Director, Sydney Melanoma Diagnostic Centre and Head of Dermatology Department, Melanoma Institute Australia (nominated Faculty Member of MIA 2016)
2014-current	Associate Professor (level 1, D), Disc. of Dermatology, University of Sydney

2. Teaching portfolio

TEACHING EXPERIENCE

Undergraduate:

- 1. Clinical supervision:** From 1995 to 2004, I regularly provided dermatology teaching to undergraduate medical students in an inpatient setting in 6 major Paris and regional hospitals.
- 2. Tutorials:** From 1995 to 1998, I gave additional and non-compulsory tutorials to medical students preparing for their medical finals on a monthly basis.
- 3. Lectures:** Since 2004, I have delivered 1 hour large group lectures on various aspects of diagnosis and management of skin cancer and, in particular, a 1 hour lecture on dermoscopy for Yr 4 Sydney Medical School students in Community Rotation.

Postgraduate:

- 1. Clinical supervision:** From 2002 to 2004, the teaching of nurses, general practitioners and specialists in an inpatient setting of Saint Louis hospital and Lariboisiere has been regularly performed. From 2008 I have supervised registrars and 1 or 2 overseas specialists/year (research fellows) at the Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital and/or Melanoma Institute Australia
- 2. Tutorials/Lectures/Seminars:** In 2008-2009: Presentations to dermatologists and pathologists in 5 major hospitals in France as invited speaker. Responsible for development and delivery of the dermoscopy course for dermatology Fellows.

Since 2010, in Australia, I have given at least 2 seminars and at least 4 invited lectures per year to specialists and general practitioners on the diagnosis and management of skin cancer.

3. Unit Development: In 2008 I designed a 2 days confocal course with Prof Giovanni Pellacani in Modena (Italy). It comprised a range of interactive teaching methods, such as case-based discussions, didactic lectures, and practical sessions. This course is still delivered in Modena at least four times a year and recognised internationally. Living in Sydney, I have designed an equivalent course for the Asia Pacific region. The first of these courses was held in May 2013.

In 2011, I developed an online teaching module for general practitioners on non-melanoma skin cancer for LEO Pharma Pty Limited. In 2012, I have participated in a 6h course In Touch: “Managing skin lesions in general practice”; This is a structured education programme designed to expand participants’ understanding of dermatological conditions, their diagnostic techniques and therapies, with the intent of achieving demonstrable improvements in clinical practice. This course was accredited by the Royal Australian College of General Practitioners, and supported by LEO Pharma Pty Limited.

4. Post graduates supervision: I have been the co-supervisor of 3 Masters of students at Paris V University in 2002-2004 who had all succeed. After my relocation in Australia, I had passed in 2013 the registration as a Research Supervisor of Higher Degree Research Candidates, University of Sydney.

As one of Australia’s few academic dermatologists, I am well known to students via the dermatology curriculum and my own translational research program, and so am well placed to recruit high-quality HDRs.

Because of my international stature, I receive requests (monthly) to host overseas fellows interested in my research. For example, I was invited to collaborate with a team at University hospital of Barcelona (Profs Malvehy, Puig and Segura) on dermoscopy and CM projects that resulted in 3 publications (one 1st author), and a CM workshop in Barcelona. Since then they send me 2 overseas fellow Dr Tatiana Moraes who is still collaborating with me on the OCT project and now establish in Sao Paulo, Brazil and Dr Helena Collgros who has led to 3 papers. Since 2010, I have always supervised one dermatologist fellow staying for more than 6months. They were coming from Ireland, Brazil,

Chili, Spain, France and England. I also manage a registrar in dermatology and one research assistant at SMDC and one at MIA.

SELF-EVALUATION OF TEACHING AND STUDENT LEARNING

Lecturing and Large Group Teaching

All my lectures are given in power-point format with multiple images and examples. In general, I supply printed lecture notes with major points detailed. I give a structured presentation, with an opening providing the framework of the talk, each sub-topic being clearly defined by signposts (both oral and visual) and a summary of the sub-topic at its conclusion. Each sub-topic is logically linked and each important point highlighted both orally and visually. Many of my lectures are on the diagnosis of skin tumours and I maintain interest by giving a clinical history with some of the lesions shown, and pose management questions around these specific clinical examples. In this way the immediate clinical relevance of the issues being taught is transmitted to the audience. I always encourage students/ doctors' reactions during the presentation, enabling greater explanation of sub-topics not clearly understood. All lectures have a set time allocated for other questions. The majority of my lectures are to post-graduates. Here, assessments of their learning are usually in the form of a formal quiz (at the conclusion of the presentation).

Recent Student/peers evaluations

1. Undergraduate: For example, at the undergraduate lecture evaluation (Yr 4 graduate medical program: Dermatology) 75% of the students gave my one hour lecture "excellent" and 25% "good". There were no "satisfactory" or "needs improvement" responses.

2. Postgraduate:

Seminar: 2 hr "Diagnosis of Pigmented Lesions & Dermoscopy" for the Royal Australian College of General Practitioners: The evaluations were "excellent" or "good" with no "fair" responses

Lectures: The evaluations at the annual meeting of the American Academy of Dermatology during the confocal symposium and the melanoma guidelines courses (1 = Unacceptable, 5 = Excellent) since 2012 have always been > 4.5

These evaluations have been judged outstanding by the American Academy of Dermatology and translate in an invitation every year since my 1st invitation in 2012. The fact they ask me in particular to contrast the Australian Guidelines to the USA ones for melanoma is showing that they see me as one of the most prevalent expert in this field from Australia.

EVIDENCE OF RESEARCH IN TEACHING.

Invitations to teach at other institutions.

I have been invited to teach at other institutions on various aspects of skin cancer (primarily to postgraduates) in Europe, America North and South, Japan and Australia at least on a bi annual basis. The later includes invited presentations to teach dermatologists at the European and the American Academy of Dermatology on diagnosis of pigmented skin lesions. Very few Australians have been invited to speak at these institutions.

Continuing Medical Education Review:

I have been invited in France and the United States to review the state of the art in diagnosis of melanoma that this has been published in the Annals of the Dermatology and Venereology in 2008 and in Expert Review of Anticancer Therapy in 2011. I have also been invited to contrast the Australian and U.S. Melanoma Guidelines for the American Academy of Dermatology on a yearly basis since 2012. I have been part of the team reviewing the Australasian melanoma guidelines in the field of diagnosis and sole author for the confocal data.

Own training:

2007 Completed Biostatistic (advanced) and a database conception courses at Sydney University.

2013 Pass the **Research Supervisor** of Higher Degree Research Candidates, University of Sydney, online course.

2016 Media training: facing media questions and conveying a message, MIA course.

3. RESEARCH & SCHOLARSHIP

SUMMARY

Track record: I am a French dermatologist, did my PhD (with scholarship) at Institute Curie, Paris, but conducted all clinical research in Australia (with an IC grant of \$70K and USyd co-supervision) where large patient numbers expedited study completion. I was directly awarded the Fellowship of the Australasian College of Dermatology in 2008 because of my academic achievement in the field of melanoma. Following my PhD, in 2010, I was immediately recruited by MIA and SMDC.

My vision is to use my clinical expertise and research leadership to develop and apply new imaging techniques for the accurate diagnosis and management of skin cancers and melanoma. This vision has led me to train in physics and optics at the Institute Marie Curie in Paris and has enabled me to understand and influence physicists and industry in the early phase of developing innovative tools. It has also crystallised the focus of my dermatology practice on the diagnosis of melanoma and skin cancer. Furthermore, it has encouraged me to develop more national and international collaborations in order to enhance the skills and training of dermatologists to develop and use these techniques appropriately.

Publications: With only part time research (0.5FT) and 7 years post PhD, I have published 54 articles (16 as 1st author, 15 as last author); 512 citations; H index 20 and progression in citation from 11 in 2007; 57 in 2009; 103 in 2012 to a total of 1456 in September 2016 and I published an average 7 articles/y since 2012. I peer review >7 papers /y and grants for NHMRC, Cancer Australia and also French, UK, Dutch funding bodies.

Award: I have been co-recipient Premier's Award (2009) for Excellence in Translational Cancer Research (CINSW); 2012 Asia-Pacific La Roche-Posay Foundation Award Winner: Best Clinical Publication (1200\$) and Wildfire Premier's Award (\$20K) for most cited publication in 2013.

Presentations: I have more than 40 presentations on my CV with 25 International invited presentations (eg. Harvard, Oxford, Sloan Kettering, Nagoya.) and 5 chairs. I am a yearly invited speaker at the American Academy of Dermatology, which is exceptional for an Australian dermatologist. I have organized courses in Modena, Sydney and Paris most with Pr Pellacani team (Modena), as well as a workshop with Pr R Braun (Zürich) and Pr G Jemec (Denmark).

Progression: My skills are in high demand, as evidenced by my clinical trials work (> 10 RCT since 2010), my international collaborations with 18 high-profile teams mostly in Europe and USA and invitation to chair sessions at world dermatology, world melanoma and academy meetings. My output is increasing, from 4 publications per year in 2008 to 7 pubs/y since 2012. Project funding is not the norm in France; in Australia I have begun by obtaining multiple instrumentation awards (\$200K) and am AI on a CINSW Grant for Excellence in Translational Research (\$3.75m). In 2014, I have received 600K from Cancer Australia as CIA for a 3y RADICAL trial (ID 1083221 ANZMTG 02.12)

Environment: As Director of the SMDC and the Dermatology Department at MIA, I am situated at the heart of melanoma research in terms of access to large numbers of patients, multidisciplinary

collaborations, interactions with industry, and expert colleagues and mentors. I now receive patient referrals from specialists throughout NSW and interstate, as well as requests (monthly) to host overseas fellows interested in my research. I am strongly supported by the ANZ Melanoma Trials Group and MIA for clinical trials protocols, statistical analysis, ethics and grant applications. Facilities and equipment are state-of-the-art, and I had access to the first Confocal Microscopy and Optical Coherent Tomography machines in Australia. As one of Australia's few academic dermatologists, I am well known to students via my own translational research program so I am well placed to recruit high-quality HDRs.

PUBLICATIONS

Books:

Clinical Fields vol 7: Dermatology. P.Rovel-Guitera, M-X.Doré, P.Chanavaz. Editions Vernazobres 2000

Book Chapters:

- Infectious disease. P. Rovel-Guitera In: Practis Thérapeutique médico-chirurgicale. Estem 1997.
- Lentigo maligna and Amelanotic melanoma. P Guitera Reflectance Confocal Microscopy of Skin Diseases". Editors: Hofmann-Wellenhof, et al. Springer; 2012 edition
- Ebook "melanoma essentials": by the team of MIA, participation in 5 chapters.
- Ebook "melanoma for specialists": by the team of MIA, participation in 5 chapters.
- Lentigo maligna chapter in Basics of Confocal Microscopy and the Complexity of Diagnosing Skin Tumors: New Imaging Tools in Clinical Practice, Diagnostic Workflows, Cost-Estimate, and New Trends SKT Dermatologic Clinics, 2016

Editorial

1. P. Guitera, P. Bourrier, N. Basset-Seguin, L. Dubertret. Echography should become the examination of choice in detection of melanoma lymph node involvement. *Ann Dermatol Venereol*. 2004 Nov;131(11):937-9.

Continuing Medical Education Review:

2. P Guitera-Rovel, M Eun Vestergaard. Diagnosis tools of cutaneous melanoma. *Ann Dermatol Venereol*. 2008 Dec;135(12):828-34
3. P Guitera, SW Menzies. State of the art of diagnostic technology for early stage melanoma. *Expert Review Anticancer Ther*. 2011, 11(5), 715–723

Journal Articles :

4. Rovel-Guitera P, Diemert MC, Charuel JL, Laporte JL, Musset L, Chosidow O, Piette JC, Frances C. IgA antineutrophil cytoplasmic antibodies in cutaneous vasculitis. *Br J Dermatol* 2000; 143: 99-103. (IF= 4.317; **cit=24**)
5. Guitera-Rovel P, Lumbroso J, Gautier-Gougis MS, Spatz A, Mercier S, Margulis A, Mamelle G, Kolb F, Lartigau E, Avril M. Indium-111 octreotide scintigraphy of Merkel cell carcinomas and their metastases. *Ann Oncol*. 2001; 12:807-11. (**IF=6.425; cit=35**)
6. Ingen-Housz-Oro S, Viguier M, Guitera-Rovel P, Verola O, De Kerviler E, Girault N, Dubertret L. Painful bruising syndrome mimicking cellulitis of the leg. *Ann Dermatol Venereol*. 2002;129:1029-32. (**IF=0.391;cit=2**)

7. Vagamon B, Dupuy A, Fontaine J, Guitera-Rovel P, Lebbe C, Morel P, Rybojad M. Acquired circinated ichthyosis revealing a lymph node tuberculosis. *Ann Dermatol Venereol*. 2003;130:635-7. **(IF=0.391)**
8. A Levy, P Guitera, D Kerob, L Ollivaud, A Archimbeau, L. Dubertret, N. Basset Seguin. Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma. *Ann Dermatol Venereol*. 2006 Feb;133(2):157-60. **(IF=0.391;cit=7)**
9. P Guitera, S Menzies. Recognising lentigo maligna. *Medical Observer*. 2006 feb: 32.
10. H Kittler, P Guitera, L Teban, M Avramidis, M Fiebinger, AR Weger, M Dawid, S Menzies. The identification of clinically featureless incipient melanoma using sequential dermoscopic imaging. *Arch Derm*, 2006 Sep;142:1113-9. **(IF=3.888;cit=136)**
11. G Pellacani, P Guitera, C Longo, M Avramidis, S Seidenari, S Menzies. The impact of in vivo reflectance confocal microscopy for the diagnostic accuracy of melanoma and equivocal melanocytic lesions, *Journal of Investigative Dermatology* 2007;127:2759-65. **(IF=6.314;cit=264)**
12. SW Menzies, J Kreusch, K Byth, M Pizzichetta, A Marghoob, R Braun, J Malvey, S Puig, G Argenziano, I Zalaudek, H S Rabinovitz, M Oliviero, H Cabo, V Ahlgrimm-Siess, M Avramidis, P Guitera, HP Soyer, G Ghigliotti, Mtanaka, A Perusquia, R Bono, L Thomas, G Pellacani, D Langford, D Piccolo, K Westerhoff, I Stanganelli, AL Manes, RJ, AW Kopf. Dermoscopic evaluation of amelanotic and hypomelanotic melanoma. *Archives of Dermatology* 2008;144(9):1120-7. **(IF=3.888;cit=160)**
13. S Segura, G Pellacani, S Puig, C Longo, S Bassoli, P Guitera, J Palou, SW Menzies, S Seidenari, J Malvey. In vivo microscopic features of nodular melanomas: dermoscopy, confocal microscopy and histopathological correlates. *Archives of Dermatology* 2008, 144(10):1311-20. **(IF=3.888;cit=67)**
14. P Guitera, L Li, K Crotty, P FitzGerald, R Mellenbergh, G Pellacani, SW Menzies. Melanoma histological Breslow thickness predicted by 75 MHz ultrasonography. *Br J Dermatol* 2008; 159(2): 364-9 (IF= 4.317;**cit=57**)
15. P Guitera, G Pellacani, C Longo, S Seidenari, M Avramidis, SW Menzies. In vivo reflectance confocal microscopy enhances secondary evaluation of melanocytic lesions. *Journal of Investigative Dermatology*, 2009; 129(1):131-8. **(IF=6.314;cit=128)**
16. G Pellacani, C Longo, G Ferrara; AM Cesinaro, S Bassoli, P Guitera, SW Menzies, S Seidenari. Spitz nevi: in vivo confocal microscopic features, dermoscopic aspects, histopathologic correlates and diagnostic significance. *J Am Acad Dermatol*. 2009;60(2):236-47. **(IF=3.991;cit=49)**
17. G Pellacani, M Vinceti, S Bassoli, R Braun, S Gonzalez, P Guitera, C Longo, A Marghoob, S W Menzies, S Puig , A Scope, S Seidenari, J Malvey. Reflectance confocal microscopy features of melanocytic lesions: an internet-based study of the reproducibility of terminology. *Archives of Dermatology*, 2009;145(10):1137-43. **(IF=3.888;cit=54)**
18. P Guitera, G Pellacani, K A Crotty, R A Scolyer, L-X L Li, S Bassoli , S Seidenari, M Vinceti, S W Menzies. The impact of in vivo reflectance confocal microscopy on the diagnostic accuracy of lentigo maligna and equivocal pigmented macules of the face. *Journal of Investigative Dermatology*. 2010;130(8):2080-91. **(IF=6.314;cit=145)**
19. P Guitera, P Bourgeat , JR Stretch, RA Scolyer, S Ourselin, Lean C, JF Thompson, R Bourne. Diagnostic value of 8.5 T magnetic resonance spectroscopy of benign and malignant skin lesion biopsies. *Melanoma Res*. 2010;20(4):311-7. **(IF=2.187;cit=3)**
20. P Guitera, L X Li, R A. Scolyer, S W Menzies. Morphological features of melanophages under in vivo reflectance confocal microscopy. *Arch Dermatol*.2010;146(5):492-8. **(IF=3.888;cit=25)**
21. Levy JL, Guitera P, Salomon D. Evaluations and measures in dermatology: new approaches. *Rev Med Suisse*. 2011 Apr 6;7(289):759-60, 762-3
22. P Guitera, SW Menzies. State of the art of diagnostic technology for early-stage melanoma. Expert review of anticancer therapy. 2011, 11(5), 715-723 (cit=23)

23. P Guitera, Scolyer RA, Gill M, Akita H, Arima M, Yokoyama Y, Matsunaga K, Longo C, Bassoli S, Bencini PL, Giannotti R, Pellacani G, Alessi-Fox C, Dalrymple C. Reflectance confocal microscopy for diagnosis of mammary and extramammary Paget's disease. *J Eur Acad Dermatol Venereol*. 2012 27(1):e24-9. (IF=2.98; cit=18)
24. Longo C, Soyer HP, Pepe P, Casari A, Wurm EM, Guitera P, Pellacani G. In vivo confocal microscopic pattern of fibroepithelioma of pinkus. *Arch Dermatol*. 2012;148(4):556. (IF=3.888; cit=10)
25. Guitera P, Menzies SW, Longo C, Cesinaro AM, Scolyer RA, Pellacani G. In Vivo Confocal Microscopy for Diagnosis of Melanoma and Basal Cell Carcinoma Using a Two-Step Method: Analysis of 710 Consecutive Clinically Equivocal Cases. *J Invest Dermatol*. 2012;132(10):2386-94(IF=6.314; cit=143)
26. S Menzies, F Moloney, K Byth, M Avramidis, G Argenziano, I Zalaudek, R Braun, J Malvehy, S Puig, H Rabinovitz, M Oliviero, H Cabo, R Bono, M. Pizzichetta, M Claeson, DGaffney, P Soyer, I Stanganelli, R Scolyer, P Guitera, J Kelly, O McCurdy, A Llambrich, AA. Marghoob, P Zaballos H Kirchesch, D Piccolo, J Bowling, L Thomas, K Terstappen, M Tanaka, G Pellacani, G Pagnanelli, G Ghigliotti, B Carlos Ortega, G Crafter, A Perusquía Ortiz, ITromme, I Kilinc Karaarslan, FOzdemir, A Tam, C Landi, P Norton, NKAçar, L Rudnicka, M Slowinska ,O Simionescu, A Di Stefani, J Kreusch. Dermoscopic evaluation of nodular melanoma. *JAMA Dermatol*. 2013;149(6):699-709 (IF=5.1; cit=34)
27. Y Bogun, RA. Scolyer, P Guitera. Asymptomatic linear pigmentation of the skin. *Intern Journal of Dermatol. Int J Dermatol*. 2013 ;52(8):935-7 (IF=1.777; cit=2)
28. P Guitera, Moloney FJ, Menzies SW, Stretch J, Quinn MJ, Hong A, Fogarty G, Scolyer RA. Improving management and patient care in lentigo maligna by mapping with in vivo confocal microscopy. *JAMA Dermatol*. 2013;149(6):692-8 (IF=5.1; cit=42)
29. Fogarty GB, Hong A, Scolyer RA, Lin E, Haydu L, Guitera P, Thompson J. Radiotherapy for lentigo maligna - a literature review and recommendations for treatment. *Br J Dermatol*. 2013; 170(1):52-8.(IF= 4.317;cit=26)
30. Losi A, Longo C, Cesinaro AM, Benati E, Witkowski A, Guitera P, Pellacani G. Hyporeflective pagetoid cells: A new clue for amelanotic melanoma diagnosis by reflectance confocal microscopy. *Br J Dermatol*. 2013; 171(1):48-54. (IF= 4.317; cit=17)
31. Zalaudek I, Cota C, Ferrara G, Moscarella E, Guitera P, Longo C, Piana S, Argenziano G. Flat pigmented macules on sun-damaged skin of the head/neck: Junctional nevus, atypical lentiginous nevus, or melanoma in situ? *Clin Dermatol*. 2014; 32(1):88-93. (IF=2.341;cit=18)
32. P. Guitera, L.E. Haydu, S.W. Menzies, R.A. Scolyer, A. Hong , G.B. Fogarty, F. Gallardo, S. Segura. Surveillance for treatment failure of lentigo maligna with dermoscopy and in vivo confocal microscopy: new descriptors. *Br J Dermatol*. 2014 170(6):1305-12. (IF= 4.317; cit=18)
33. A Masson, P Guitera, P Brice, I Moulouguet, F Mouly, J-D Bouaziz, M Battistella, I Madelaine, J Roux, C Ram-Wolff, J-M Cayuela, H Bachelez, A Bensussan, L Michel, M Bagot. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. *Br J Dermatol*. 2014;170(3):720-4. (IF= 4.317; cit=24)
34. Collgros H, Guitera P. Blue-grey pigmented lesions on trauma sites. *Medicine Today* 2014; 15(3): 61-63.
35. F Moloney, P Guitera, E Coates, N Haass, K Ho, R Khoury, O'Connell RL, Raudonikis L, Schmid H, G Mann, S Menzies. Detection of Primary Melanoma in Individuals at Extreme High Risk: a prospective 5-year follow-up study. *JAMA Dermatol*. 2014 150(8):819-27. (IF=5.1; cit=33)
36. Laing ME, Coates E, Jopp-McKay A, Scolyer RA, Guitera P. Atypical naevus spilus: detection by in vivo confocal microscopy. *Clin Exp Dermatol*. 2014 Jul;39(5):616-9. (IF=1.234)

37. Longo C, Lallas A, Kyrgidis A, Rabinovitz H, Moscarella E, Ciardo S, Zalaudek I, Oliviero M, Losi A, Gonzalez S, Guitera P, Piana S, Argenziano G, Pellacani G. Classifying distinct basal cell carcinoma subtype by means of dermoscopy and reflectance confocal microscopy. *J Am Acad Dermatol*. 2014; 71(4):716-724. **(IF =4.731;cit=51)**
38. Santos D, Green Julia, Bhandari N, Hong A, Guitera P, Forgarty G. Tangential Volumetric Modulated Radiotherapy – a new technique for large scalp lesions with a case study in lentigo maligna. *J. Bioautomation*. PMB-101407 **(IF = 0.612)**
39. Collgros H, Guitera P. A pearly papule with arborizing vessels. *J Am Acad Dermatol*. 2015 Jan;72(1 Suppl):S25-6 **(IF =4.731)**
40. Farnetani F, Scope A, Braun RP, Gonzalez S, Guitera P, Malveyh J, Manfredini M, Marghoob AA, Moscarella E, Oliviero M, Puig S, Rabinovitz HS, Stanganelli I, Longo C, Malagoli C, Vinceti M, Pellacani G. Skin Cancer Diagnosis With Reflectance Confocal Microscopy: Reproducibility of Feature Recognition and Accuracy of Diagnosis. *JAMA Dermatol*. 2015; 151(10):1075-80 **(IF=5.1;cit=19)**
41. Cheng HM, Guitera P. Systematic review of optical coherence tomography usage in the diagnosis and management of basal cell carcinoma. *Br J Dermatol*. 2015; 173(6):1371-80. **(IF= 4.317;cit=8)**
42. Maher NG, Collgros H, Uribe P, Ch'ng S, Rajadhyaksha M, Guitera P. In vivo confocal microscopy for the oral cavity: Current state of the field and future potential. *Oral Oncol*. 2016; 54:28-35. **(IF=3.607;cit=5)**
43. Ulrich M, Reinhold U, Skov T, Søndergaard RE, Guitera P. Histological examination confirms clinical clearance of AKs following treatment with ingenol mebutate 0.05% gel. *Br J Dermatol*. 2017;176(1):71-80. **(IF= 4.317; cit=1)**
44. Guitera P, Menzies SW, Argenziano G, Longo C, Losi A, Drummond M, Scolyer RA, Pellacani G. Dermoscopy and in vivo confocal microscopy are complimentary techniques for the diagnosis of difficult amelanotic and light colored skin lesions. *Br J Dermatol*. 2016;175(6):1311-1319. **(IF= 4.317; cit=3)**
45. Maher NG, Solinas A, Scolyer RA, Guitera P. In vivo reflectance confocal microscopy for evaluating melanoma of the lip and its differential diagnoses. *Oral Med Oral Pathol Oral Radiol*. 2017 Jan;123(1):84-94. **(IF=1.262)**
46. Star P, Guitera P. Lentigo Maligna, Macules of the Face, and Lesions on Sun-Damaged Skin: Confocal Makes the Difference. *Dermatol Clin*. 2016;34(4):421-429 **(IF=2.470)**
47. Maher NG, Blumetti TP, Gomes EE, Cheng HM, Satgunaseelan L, Lo S, Rezze GG, Scolyer RA, Guitera P. Melanoma diagnosis may be a pitfall for optical coherence tomography assessment of equivocal amelanotic or hypomelanotic skin lesions. *Br J Dermatol*. *Br J Dermatol*. 2016 Nov 18. doi: 10.1111/bjd.15187. **(IF= 4.317)**
48. HM Cheng, S Lo, R Scolyer, A Meekings, G Carlos, P Guitera. Accuracy of optical coherence tomography for the diagnosis of superficial basal cell carcinoma: a prospective, consecutive, cohort study of 168 cases. *Br J Dermatology*. 2016. 175 (6), 1290-1300 **(IF= 4.317; cit=6)**
49. Bell KJ, Mehta Y, Turner RM, Morton RL, Dieng M, Saw R, Guitera P, McCaffery. K, Low D, Low C, Jenkins M, Irwig L, Webster AC. Fear of new or recurrent melanoma after treatment for localised melanoma. *Psychooncology*. 2017 Jan 4. Doi: 10.1002/pon.4366. **(IF=2.443)**
50. Wurm E, Pellacani G, Longo C, Soyer HP, Gonzalez S, Hofmann-Wellenhof R, Ahlgrim-Siess V, Guitera P, Sinz C, Kittler H. The value of reflectance confocal microscopy in diagnosis of flat pigmented facial lesions: a prospective study. *J Eur Acad Dermatol Venereol*. 2017 Feb 18. doi: 10.1111/jdv.14171. **(IF=3.029)**
51. Maher NG, Guitera P. Imiquimod treatment for lentigo maligna - LIMIT-1 trial. *Br J Dermatol*. 2017 Mar 29. doi: 10.1111/bjd.15511. [Epub ahead of print] **(IF= 4.317)**

52. Uribe P, Collgros H, Scolyer RA, Menzies SW, Guitera P. In Vivo Reflectance Confocal Microscopy for the Diagnosis of Melanoma and Melanotic Macules of the Lip. JAMA Dermatol. 2017 May 3. doi: 10.1001/jamadermatol.2017.0504. (IF=5.1)
53. Rocha L, Menzies SW, Lo S, Avramidis M, Khoury R, Jakkett L, Guitera P. Analysis of an electrical impedance spectroscopy system in short-term digital dermoscopy imaging of melanocytic lesions.Br J Dermatol. 2017 Apr 19. doi: 10.1111/bjd.15595. [Epub ahead of print] (IF= 4.317)
54. Maher NG, Solinas A, Scolyer RA, Puig S, Pellacani G, Guitera P. Detection of desmoplastic melanoma with dermoscopy and reflectance confocal microscopy. J Eur Acad Dermatol Venereol. 2017 Jun 2. doi: 10.1111/jdv.14381. (IF= 3.029)

CONFERENCE & PRESENTATIONS:

I have >30 presentations with 25 International invited presentations (eg. Harvard, Oxford, Sloan Kettering, Nagoya.) and 5 chairs. I am a regular invited speaker at the American Academy of Dermatology, which is exceptional for an Australian dermatologist. I have organized courses in Modena, Sydney and Paris most with Pr Pellacani team (Modena), as well as a workshop with Pr R Braun (Zürich) and Pr G Jemec (Denmark).

1. Participation and Presentation at the National Dermatology Conference, Paris, 1998:
 - Ig A anti neutrophil antibodies in cutaneous vasculitis.
 - Scintigraphy of Merkel cell carcinomas and their metastases.
2. Participation and Presentation at 20th World Congress of Dermatology, Paris, 2002:
 - Post surgical localized pemphigus with isolated antidesmoplakin antibodies.
3. Participation and Presentation National Dermatology Conference, Paris, 2003:
 - Autoimmune haemolytic anaemia during alpha interferon alpha2b treatment in cutaneous T lymphoma.
4. Participation and Presentation as invited speaker at the Eurocancer, Paris, 2004:
 - Impact of sonography in the detection and follow-up of melanoma lymph node metastases.
5. Participation and Presentation National Dermatology Conference, Paris, 2004:
 - Immunoglobulin gene rearrangement in cutaneous T cell lymphoma.
 - Treatment of refractory cutaneous T cell Lymphoma with alemtuzumab..
6. Participation and Presentation at the International Dermoscopy Society, Naples, 2006:
 - The identification of clinically featureless incipient melanoma using sequential dermoscopy imaging.
7. Participation and Presentation as an invited speaker at the Australasian dermatopathology Society 27th Annual Conference, Sydney, 2006
 - In vivo reflectance confocal microscopy for the diagnosis of melanoma on the skin.
8. Participation and Presentation 21st World Congress of Dermatology, Buenos Aires, 2007:

- Salvage and maintenance treatment with alemtuzumab (anti-CD52 monoclonal antibody) in refractory peripheral T-cell lymphomas.
 - Melanoma histological Breslow thickness predicted by 75MHz ultrasonography.
 - In vivo reflectance confocal microscopy enhances secondary evaluation of melanocytic lesions.
9. Participation and presentation invited speaker at the Australasian College of Dermatology Annual Meeting, Sydney, 2008
 - In vivo reflectance confocal microscopy for the evaluation evaluation of melanocytic lesions.
 - In vivo reflectance confocal microscopy for the diagnostic of difficult lentigo maligna.
 10. Participation at European Academy of Dermatology and Venereology, Paris, 2008 and presentation invited speaker at the International Confocal Working Group
 - The impact of in vivo reflectance confocal microscopy on the diagnostic accuracy of lentigo maligna and equivocal pigmented macules of the face.
 11. Participation and Presentation as an invited speaker National Dermatology Conference, Paris, 2008
 - The impact of in vivo reflectance confocal microscopy on melanoma and lentigo maligna.
 12. Participation and presentation invited speaker at the European Academy of Dermatology and Venereology, Berlin, 2009 and the International Confocal Working Group
 - Melanoma and non melanoma skin cancer diagnosis using in vivo confocal microscopy (RCM): analysis of 549 consecutive equivocal cases.
 - The impact of in vivo reflectance confocal microscopy on the diagnostic accuracy of 110 lentigo maligna and 247 equivocal pigmented and non-pigmented macules of the face.
 13. Participation and presentation invited speaker at International Dermoscopy Society, Barcelona, 2009:
 - A case series of 14 amelanotic and hypomelanotic melanomas: new dermoscopy method and confocal microscopy contributions
 14. Participation and presentation invited speaker and chair of session at European Academy of Dermatology and Venereology, Gothenbourg, 2010
 - Melanoma and non melanoma skin cancer diagnosis using in vivo confocal microscopy (RCM): analysis of 549 consecutive equivocal cases.
 - The impact of in vivo reflectance confocal microscopy on the diagnostic accuracy of 110 lentigo maligna and 247 equivocal pigmented and non-pigmented macules of the face.
 15. Participation and presentation invited speaker and Chair of session at Melanoma 2010 Congress, Sydney. (Joint 7th International Melanoma Research Congress and 4th Melanoma & skin cancer Centres Meeting)
 - New melanoma diagnostic techniques
 - In vivo confocal microscopy diagnosis of lentigo maligna.
 16. Participation and presentation as invited speaker at the 22nd World Congress of Dermatology, Seoul, Korea, 2011, and the International Confocal Working Group.
 - Dermato oncology course
 - Confocal Microscopy Symposium
 17. Participation and presentation at the Australasian College of Dermatology Annual Meeting, Perth, 2011
 - Mapping of lentigo Maligna with in vivo confocal microscopy: outcome

18. Participation and presentation at Melanoma 2011 Congress, Templa, Florida, USA.
(Joint 8th International Melanoma Research Congress and 5th Melanoma & skin cancer Centres Meeting)
- In vivo confocal microscopy for diagnosis of melanoma and basal cell carcinoma using a 2-step method: analysis of 710 consecutive clinically equivocal cases.
19. Participation and presentation invited speaker at the American Academy of Dermatology, San Diego, California, USA, 2012 and the International Confocal Working Group.
- Guideline Based Session Melanoma
 - Strength and limits of in vivo confocal microscopy in skin cancer diagnosis.
20. Participation and presentation invited speaker at the Australasian College of Dermatology Annual Meeting, Brisbane, 2012
- In vivo CM for diagnosis of melanoma and BCC using a 2-step method: 710 consecutive clinically equivocal cases
21. Participation and presentation invited speaker at the International Dermoscopy Society, Brisbane, 2012
- Confocal microscopy for difficult macules of the face
 - Symposium: in vivo confocal microscopy for LM: multidisciplinary approach and proposition of a 2nd line protocol
22. Participation and presentation invited speaker at the National Melanoma Conference, Freemantle, 2012
- Advances in Melanoma Diagnosis
23. Participation and presentation invited speaker at the American Academy of Dermatology, Miami, Florida, USA, 2013 and the International Confocal Working Group.
- W013: Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines
 - S013: Reflectance Confocal Microscopy: Current & Future
24. Presentation as invited speaker in the Nagoya Dermatology Department (biggest hospital in Japan): New diagnosis tools for the diagnosis of melanoma.
25. Participation and presentation invited speaker at the Australasian College of Dermatology Annual Meeting, Sydney, May 2013:
- Organisation of the workshop: In vivo confocal microscopy dermatology workshop: is there a place for confocal microscopy in the Australian community?
 - Clinical diagnosis and imaging of melanoma
 - Cutaneous adverse effects of BRAFi
26. Participation and presentation speaker at 8th World Congress of Melanoma in Hamburg, Germany, July 2013
- Workshop on consensus terminology and guidelines for *in vivo* confocal microscopy
 - A Phase III trial of imiquimod topical treatment versus radiotherapy for lentigo maligna (LM) mapped with reflectance confocal microscopy
27. Participation and presentation invited speaker at the American Academy of Dermatology, Denver, Colorado, USA, March 2014 and the International Confocal Working Group.
- W013: Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines
 - F117: Reflectance Confocal Microscopy: Current & Future

28. Participation and presentation invited speaker at the American Academy of Dermatology, San Francisco, USA, March 2015 and the International Confocal Working Group.
- W024: Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines
 - F145: Reflectance Confocal Microscopy: Current & Future
 - F128 - Non-Invasive Imaging in Dermatology
29. Presentation invited speaker at the Trans Tasman Radiation Oncology Group (TROG Cancer Research), 27th Annual Scientific Meeting, March, 2015 at City Hall, Newcastle, NSW.
- Collaboration of dermatologists and radiotherapists in the field of skin cancer and melanoma
30. Participation and supervision of presentation and posters of 2master students and registrar at the Australasian College of Dermatology Annual Meeting, Adelaide, May 2015
- Optical Coherence Tomography in the Presurgical Margin Delineation of Mohs Surgery in Infiltrative BCC. Hui Mei Cheng, Pascale Guitera and Rhonda Harvey
 - Assessment of the Optimal Interval for Digital Dermoscopy Monitoring for the Evaluation of Pigmented Nail Lesions. Hui Mei Cheng, Pascale Guitera
 - Reflectance confocal microscopy as a diagnostic aid in determined invasion in lentigo maligna clinical presentation. Giuliana carlos, Pascale Guitera
31. Participation and presentation invited speaker and chair of session 23th World Congress of Dermatology, Vancouver, Canada, June 2015
- Triage of BCC with optical coherence tomography
 - RCM cases form Australia
32. Participation and presentation invited speaker at the American Academy of Dermatology, Washington, USA, March 2016; the International Confocal Working Group and the OCT focus Group.
- F002: Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines
 - C022: Advanced course of dermoscopy
 - Melanocytic hyperplasia, so what? (presented by Dr Rocha, PhD supervised since 2015)
 - BCC and amelanotic melanoma with OCT: when we should biopsy?
33. Participation and presentation invited speaker and chair of session at the Australian Melanoma Conference, Sydney October 2016
- Learning dermoscopy & confocal course
 - Multidisciplinary meeting – the lentigo maligna model
 - New technologies - in practice and in the future.
34. Participation and presentation invited speaker at the American Academy of Dermatology, Orlando, USA, March 2017; the International Confocal Working Group and the OCT focus Group.
- F139: Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines
 - C004: Advanced course of dermoscopy
 - In Vivo Reflectance Confocal Microscopy for the Diagnosis of Melanoma and Melanotic Macules of the Lip.(presented by Dr Uribe, overseas fellow supervised in 2013)
35. Participation and presentation as invited speaker; Supervision of presentations and posters of 2master students at the Australasian College of Dermatology Annual Meeting, Sydney, May 2017
- Investigator initiated, randomised controlled phase II trial of Imiquimod cream versus radiotherapy for patients with complex lentigo maligna.

- Blue-grey pigmented lesions on trauma sites Helena Collgros, Pascale Guitera
- Defining Lentigo Maligna and its Margins and Identifying Predictors of Recurrence: Correlation of Clinical, Dermatoscopic, Confocal Microscopy and Histopathological Data. Phoebe Star, Pascale Guitera
- Desmoplastic Melanoma: A diagnostic Difficulty. Nigel Maher, Pascale Guitera
- In Vivo Reflectance Confocal Microscopy of the lip, from normal to sun damaged (poster, Helena Collgros); a case of pustular psoriasis in context pembrolizumab. (Poster, Phoebe star)

WORKSHOPS;

1. Workshop on in vivo confocal microscopy at the National Dermatology Conference, Paris, 2008 and 2009
2. With the sponsorship of Lucid and the MIA from 2010 to 2014, meetings for presentations and propositions of collaborations at:
 - Boston, Havard, Melanoma Groups
 - University of Connecticut, Dermatology Department
 - Yale, Melanoma Group
 - Memorial Sloan Kettering, Melanoma group, NY.
 - Institut Gustave Roussy, Paris,
 - Oxford Melanoma Group, England
 - St George and St Thomas Melanoma Group, London
3. Workshop on Diagnosis and management of lentigo maligna as a member of the Scientific Committee at the International Dermoscopy Society, 2012.
4. Organized 1 or 2 days workshop and courses on advance dermoscopy and in vivo confocal microscopy in Australia since May 2013 with the sponsorship of Caliber, Inc. and MIA.
5. Workshop on consensus terminology and guidelines for in vivo confocal microscopy in Hambourg, Germany in July 2013.
6. Principal speaker at the Curso de Dermatoscopia do Nucleo de Cancer de Pele, AC Camargo Cancer Center, San Paolo, December 2015.

FUNDED RESEARCH AWARDS

1. Federation Nationale des centres de Lutte contre le cancer and La fondation de France: P Guitera, Mobility grant 002678; \$70,000 ; 2005 over 2y.
2. NSW Cancer Institute instrumentation grant: In vivo confocal microscope for the diagnosis of skin cancer and melanoma. SW Menzies, P Guitera: \$110,000; 2005

3. Philanthropic donation from Mr Poche: In vivo confocal microscope for the diagnosis of skin cancer and melanoma. P Guitera: \$100,000; 2010
4. Philanthropic donation from patients: Mr Gray, Mr Petre and Mrs Lewis: 2 hand-held in vivo confocal microscopes for the diagnosis of skin cancer and melanoma. P Guitera: \$30,000; \$40000 and \$16000 respectively. New automated total body photography systems at MIA and RPA 540000US\$
5. Cancer Institute NSW Program Grant for Excellence Translational Research, AI;10/TPG/1-02: \$3,750,000 2010-2015 (750 000 per yr for 5 yrs)
6. RANZCR Research Grant, CIB, pilot of the RADICAL trial (\$60000 for 1y)
7. Cancer Australia, Collaborative Cancer Research Scheme, CIA for a 3y RADICAL trial (ID 1083221 ANZMTG 02.12) \$600K for 3y
8. F&E Bauer Foundation Scholarship, 2016: 'NSW Lentigo Maligna Melanoma Study': 25K for 1y.

COLLABORATORS OF HIGH STATURE

International:

As a member of the French Dermatology Society and due to my prestigious fellowship at Saint Louis Hospital, which has the largest dermatology dept in France, I have collaborated with many French scientists in my field. A highlight is my work with Profs Avril and Robert (Curie Institute and Institute Gustave Roussy [IGR]) on skin cancer diagnosis, which has resulted in 6 journal articles (two 1st author), a book, a book chapter, and an editorial (all as 1st author). In 2014, I organized a meeting in Paris between the IGR team and 12 senior consultants from the Melanoma Institute Australia to facilitate multidisciplinary collaborations in the melanoma field.

H Kittler (University Hospital of Vienna) invited me to collaborate in the study of digital monitoring that has changed Australian guidelines on diagnosing incipient melanoma.

I have also been invited to collaborate on several multi-centre dermoscopy projects with researchers in the US (Sloan Kettering, New York; U Miami), Italy, Switzerland, Argentina, Austria, Ireland, and of course Australia. These have resulted in 7 publications and an invitation to join the scientific committee of the International Dermoscopy Society (IDS) for which I led a workshop on lentigo maligna management in 2012.

I have a long-standing collaboration with Prof Pellacani (Uni of Modena), world leader in confocal microscopy (CM). Since 2005, I have steadily worked with his team on CM projects and we have developed a world-renowned diagnostic method resulting in 15 papers (8 as 1st or last author).

On similar projects, I have initiated collaborations with Dr Rabinovitz (Uni of Miami) on CM of lentigo maligna and a team at Nagoya University (Japan) and in New York on CM of Paget's disease. I have been invited to collaborate with S Segura (Barcelona) on CM of nodular melanoma and then management of lentigo maligna.

My work with physicists (Curie Institute, Sloan Kettering) has enabled me to establish an Australian platform for evaluating and refining new diagnostics technologies with industry collaborators, eg. Caliber (US), Michelson (UK) and MoleMap (Aust). As a result of these collaborations I have been invited to organize courses in new diagnostic tools in Modena, Sydney and Paris, mostly with Prof Pellacani's team, a workshop with Prof R Braun (Zürich Uni), a symposium with Prof G Jemec (Copenhagen Uni). Also, Prof Hofmann-Wellenhof (Graz Uni) asked me to write the 2 main chapters in the CM atlas reference book.

National:

Prof Menzies, the eponymous inventor of a dermoscopy method used worldwide and the most well-known Australian researcher in the field, was my PhD co-supervisor in Sydney and my main mentor. I co-authored 20 publications with him (eight 1st author) and recently replaced him as Director of the SMDC at RPAH. Prof Scolyer (The University of Sydney) is one of the world's top 10 experts in melanoma pathology.

Together we are working on establishing correlations between pathology and various diagnostic tools. To date, this has resulted in > 10 papers and co-supervision (ongoing) of 4 Master students.

I have ongoing collaborations with oncologists at MIA and Westmead on RCTs of new drugs, in particular characterizing skin side effects; with radiotherapists at RPAH and St Vincent's Hospital (2 articles); and with plastic surgeons at MIA (2 articles). As a result of my collaborations in every discipline of the melanoma field, I am now regularly invited to speak at the American Academy of Dermatology

RESEARCH AWARDS

1. **2009 Congratulations of the Jury:** highest award for Doctor es sciences at the Doctoral School of Cancer 0418, Paris XI University, 'New imaging methods for the diagnosis of primary cutaneous melanoma and its metastasis.'
2. **2009 Premier's Award for Excellence in Translational Research.** Our research team (Mann G, Thompson J, Kefford R, Scolyer R, Hersey P, Menzies S, Spillane A, Rizos H, Zhang X, Christopherson R) won this award for progress within the CINSW translational research grant.
3. **2012 Asia-Pacific La Roche-Posay Foundation Award Winner (1200\$):** Best Clinical Publication

4. **2013 Wildfire Premier's award for outstanding research (20K)** for most cited publication in 2013.

CONTRIBUTION TO RESEARCH ORGANISATIONS

1. Some journals acting as a reviewer:

I am reviewing at least 7 articles per year for all major peer reviewed journals of my discipline:

Archives of Dermatology

Journal of Investigative Dermatology

British Journal of Dermatology

Journal of the American Academy of Dermatology

Melanoma Research

The Australasian Journal of Dermatology

Journal of the European Academy of Dermatology and Venereology

Acta Dermatologica

Plos one....

2. Reviewing grants for

- Agence National de la Recherche:
 1. In-vivo validation of a 2D multispectral analysis device for normal and diseased human skin. Cost **414 432 €** ;
 2. Innovative solution allowing to detect and characterize progress over time of a skin cancer, using a standardized methodology and equipment, for the use of specialized and general physicians. Cost **952 942 €**
- Guy's & St Thomas' Charity: Multilaser confocal microscopy. Cost 144,222£
- NMHRC Funding Round:
 1. 2013_Project Grant_funding_commencing_2014 Application ID: APP1069408
Application Name: Getting melanoma right!: The accuracy of 'thin' stage 1 melanoma diagnosis in Queensland. **\$395,600**
 2. 2014_Project Grant_funding_commencing_2014 Application ID: APP1085794
Application Name: Characterisation of Melanoma with Terahertz Laser Imaging: Validation in the Mouse Model **\$285,341**

3. 2015_CRE in Clinical Research_funding_commencing_2016

Primary Spokesperson:

Application ID	Application Title	CIA
APP1116555	Minimise Error Rates in Mammography Interpretation and Diagnosis (MERMaID)	Professor Patrick Brennan

Secondary Spokesperson:

Application ID	Application Title	CIA
APP1116468	Centre for Research Excellence in Chronic Pain	Professor Nigel Bunnett
APP1116517	NHMRC Centre for Physiotherapy Clinical Research Excellence	Professor Chris Maher
APP1117216	Ending HIV and its Complications	Professor Jennifer Hoy

- Review of the Final Economic evaluation of Skin Cancer social costs - Cost Analysis 24.10.13 for the NSW Cancer Institute
- The Dutch Cancer Society (KWF Kankerbestrijding) leading funding agency for cancer research in the Netherlands: Reflectance confocal microscopy as a non-invasive diagnostic tool to improve skin cancer diagnosis and care" Project number: KUN 2014-00006563; € **386,000**
- The City of Dublin Skin & Cancer Hospital Charity : review of Nodular Melanoma – Unravelling the Genetic and Epigenetic Profile and link to Stem Cell Microenvironment. € **229,200**
- Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Part of the Cancer Australia Grant Review Committee; reviewing **12 grants**; November 2016

3. Review of thesis

For the University of Queensland: 2014, s4022177: Identifying Molecular Changes in Naevi Driving Early Stage Melanoma

For the University of Queensland: 2017, s40560087: Prognostic factors in early stage invasive melanoma”

4. Research administration

Responsible for Sydney Local Health Network application and administration for all clinical trials under my direct supervision (8 current trials)

5. Expertise for the college of dermatology:

Australasian College of Dermatologists Representative on CS-042 Sunscreen Agents Committee at Standards Australia/Standards New Zealand Committees. 2014-2017

6. Review of the Australasian Melanoma guidelines:

Diagnosis questions in 2016 with Pr. Menzies lead: review all the literature since 2008; synthesize new evidences and recommendations.

Sole author of In vivo confocal microscopy review.

Total Body Photography in 2017 with Pr. Kelly's lead

Spread of these new recommendations through annual talk nationally and at the American Academy of dermatology.

DISSEMINATION AND POPULARISATION OF RESEARCH

- 2005- Voluntary participation in the French day of free diagnosis of melanoma and skin cancers.
- 2006- Medical observer “Recognising lentigo maligna”
- 2009 -Development of the Melanoma Institute Australia pamphlet “Melanoma, early detection and treatment could save your life”
- 2011 ABC TV, Tonic health magazine - episode nine: on how early detection of melanoma could halve death rates.
- 2012- current Training of Melanoma Institute Australia ambassadors for National Shade Day and fund raising events.
- 2012- Petit Journal “puts sunbeds to bed“.
- 2012- The Scott Kirkbride Melanoma Research Centre 2h patient forum.
- 2009-current: Writing information for the general public and doctors on risk factors, UV protection, melanoma and skin cancers diagnosis for the public on Melanoma Institute Australia web site and pamphlet
- 2011-current: Board Expert of the website www.uv-damage.org that covers all aspects of the major fields of prevention of sun exposure damages with updated scientific material and dedicated to physicians being relevant to their practice.
- 2002-current: Small consultancy projects and interviews for Leo-Pharma, La Roche Posay, Avene, MRA research, Cedgim strategy, Biotherm, GlaxcoSmithkine...
- 2014- Write information on sun cream for the Australasian College of Dermatologist website
- 2016-current: Cancer Council NSW - skin cancer card for general practitioners- regular updates.
- 2016-current: launch and dissemination of YOUdermoscopy, application to learn dermoscopy developed by Avene.
- 2015-current: Author and supervision of Melanoma Research Review publications (3/y) with a synthesis and expert comments of 10 main articles published in the field intended for Australian medical professionals

4. Service & Leadership in the University & Discipline

APPOINTMENTS

1- International Dermoscopy Society

Scientific Committee, International Dermoscopy Society (2011→)

2- International Confocal Microscopy Working Group.

Contribution to the design of the Vivanet study (3 days in Barcelona, Spain 2008) and confocal advanced course (3days in Modena, Italy 2008) as invited teacher. In 2012 I was asked to be the Australasian representative of this newly organised association involved with all aspects of in vivo diagnosis of skin disorders with confocal microscopy.

3- Optical Coherence tomography focus group: Regular invited speaker and member

4 -Regular invited speaker and member of the French Society of Dermatology, American Academy of Dermatology, Australia and New Zealand Melanoma Trials Group, Australian College of Dermatology, Skin and Cancer Foundation, Sydney Catalyst.

5- Faculty of Melanoma Institute Australia and appointment in Clinical committee of MIA (2017→)

: The function of MIA Faculty is to inform, advise and support the governance and leadership team of MIA on matters related to any and/or all of the three pillars of MIA's purpose: treatment, research and education. The Clinical committee ensures the timely, efficient, comprehensive provision of clinical services at MIA and advise the Medical Director(s) on issues relevant to the Committee's Terms of Reference

RECENT PROFESSIONAL ACTIVITY

1- Director of the Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital

I am working 0.5 FTE at SMDC where I do part time research and part time outpatient clinics and surgery. The SMDC mission statement is to apply best practice methods for the diagnosis and management of skin tumours, with a particular emphasis on pigmented lesions (eg. moles and melanoma) and to conduct research on diagnostic and therapeutic techniques for skin tumours. There are currently 2 consultant dermatologists working in the unit, with additional training opportunity for medical students from Sydney University.

2- Director of the Dermatology Department, Melanoma Institute Australia, NSW

I am working working 0.5FTE at MIA where I do part time research and part time outpatient clinics and surgery. I was recruited in 2009 to develop the Dermatology Department of MIA. The first patient has been booked in February 2010 and dermatologists have now followed more than 3000 patients. We are 5 consultants and have organised a rotation of registrars with the Skin & Cancer Foundation from 2014 and onward. MIA is the largest (patient/year intake) melanoma unit in the world and I collaborate on a daily basis with plastic surgeons, radiotherapists, pathologists and oncologists. My experience is recognised in the diagnosis and management of all presentations of cutaneous and metastatic melanoma but also benign, premalignant and other malignant skin tumours. I regularly receive patient referrals from specialists and multiple referrals are from interstate. I am involved in weekly multidisciplinary meeting

- I am responsible for the High risk Clinic at MIA and take care difficult of melanoma and skin cancer' patients, in particular using in vivo confocal microscopes to map the area to treat, target biopsy and/ or detect recurrence.
- I have launched and leaded a Multidisciplinary Lentigo Maligna Clinic with dermatologists, plastic surgeons, radiotherapists and pathologists to review difficult management issues, develop trials and new guidelines. This clinic is run once a month and attracts national attention.
- Participation and international collaborations on major randomised trials of BRAF Inhibitors, MEK inhibitors and combinations, vaccination and new immunomodulators for the treatment of metastatic melanoma (major studies are MSLT2, Mel-D, Roche BRAF, EAP, GSK Combi V, GSK Combi D, GSK DERMA). We are now using most of these new drugs in adjuvant setting with major trials . We are leading a dermatology working group on the cutaneous side effects of these new melanoma drugs.